Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brazilian lung cancer study seeks to map Real-World treatment patterns

NCT ID NCT06491862

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study reviews medical records of 250 adults in Brazil with advanced non-squamous non-small cell lung cancer whose cancer progressed after platinum-based chemotherapy. Researchers will describe patient characteristics, treatments used, and outcomes in routine practice. The goal is to understand how these patients are managed in the real world, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal real-world treatment patterns and outcomes, helping doctors make better decisions for lung cancer patients in Brazil.
What could go wrong
This is an observational study that does not test a new treatment, so it cannot directly improve patient care. Results may be limited by incomplete medical records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of sequential adult patients in study sites with a diagnosis of IIIB/IIIC/IV non-squamous NSCLC with or without AGA and received at least 1 line of treatment after failing PTC for a/m NSCLC with a start date between January 2017 and December 2024.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB/IIIC not eligible for curative-intent therapies or stage IV/M1 (a/m NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2) * Aged at least 18 years at first diagnosis of a/m NSCLC * For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy. * For the non\_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC) * Patient must have received at least line of therapy of an active agent after failing PTC. Exclusion Criteria * Patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts. * Patients who participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2018 onward.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-squamous non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-squamous non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Belo Horizonte, Minas Gerais, 30110-934, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Belo Horizonte, Minas Gerais, 30380-420, Brazil

  • Research Site

    RECRUITING

    Natal, Rio Grande do Norte, 59062-000, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Porto Alegre, Rio Grande do Sul, 90560-032, Brazil

  • Research Site

    NOT_YET_RECRUITING

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Research Site

    RECRUITING

    São Paulo, 01308-050, Brazil

  • Research Site

    NOT_YET_RECRUITING

    São Paulo, 01323-001, Brazil

  • Research Site

    RECRUITING

    São Paulo, 01323-020, Brazil

  • Research Site

    RECRUITING

    São Paulo, 01333-010, Brazil

  • Research Site

    NOT_YET_RECRUITING

    São Paulo, 01509-010, Brazil

  • Research Site

    RECRUITING

    São Paulo, 05652-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.